Genocea Biosciences Inc. (GNCA) announced Thursday morning that GEN-003 demonstrated sustained and statistically significant reductions in the rate of viral shedding 12 months after dosing in its Phase 2 trial, for the treatment of genital herpes.
from RTT - Before the Bell http://ift.tt/1UHkfkH
via IFTTT
No comments:
Post a Comment